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ABSTRACT 
Takotsubo cardiomyopathy (TTC) is an acute cardiac condition resembling in symptoms acute 
coronary syndrome (ACS), but without obstructive coronary artery disease. TTC develops almost 
solely in post-menopausal women and usually after preceding stress. Of all patients with ACS 
symptoms, TTC incidence is 2%. Due to similar symptoms and findings, differential diagnosis 
requires coronary angiography (CAG). 
The pathophysiology of TTC is unknown. Even though the accumulated evidence 
suggests a causative role for a catecholamine surge, other theories exist. Aborted myocardial 
infarction (MI) produces similar electrocardiography (ECG) and biochemical findings as in TTC. In 
such cases, because of non-stenotic coronary artery plaques, a dissolved coronary thrombus might 
show no any signs in the CAG, which could lead to an assumption of non-atherothrombotic etiology 
for the heart attack. In ACS, altered levels of proteolytic enzyme called matrix metalloproteinase 8 
(MMP-8), and its inhibitor, the tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), associate to 
plaque rupture. Their direct comparison between ACS and TTC remains unknown. 
 The purpose of this thesis is to test whether either of two non-invasive methods: the 
ECG (I) or MMP-8 and TIMP-1 (III), could differentiate TTC from ACS. We also set out to find 
whether, after all, what is responsible for the TTC is transient thrombosis in the coronary circulation 
(II). 
 Both our prospective and retrospective collection of patients resulted in 92 TTC cases. 
The demographics of our material were similar to those of other TTC reports worldwide. In the ECG 
study (I), a review and comparison of 57 TTC and ACS acute ECGs resulted in criteria differentiating 
the two with 63% sensitivity and 93% specificity. In cases of suspected ST-elevation myocardial 
infarction, such accuracy is insufficient for a decision against coronary intervention. 
Blood samples from 45 TTC patients and matching numbers of ACS patients and 
controls were analyzed for coagulation markers. Despite the similar acute-phase reaction in TTC and 
ACS patients, the TTC d-dimer levels matched those of controls, and were lower and less frequently 
above reference level than with those in ACS. The blood samples were further analyzed for MMP-8 
and TIMP-1 levels showing, on admission, better differentiation between TTC and ACS by TIMP-1 
than by troponin T (TnT). In TTC, low ejection fraction (EF) correlated with low MMP-8/TIMP-1 
ratio.  
 8 
 In conclusion, ECG lacked the ability to differentiate TTC from ACS that would have 
allowed avoidance of invasive diagnostics. Secondly, the coagulation results supported 
catecholamine and argued against the thrombosis theory. Finally, TIMP-1 emerged as a potential 
future biomarker in differentiation between ACS and TTC.  Furthermore, in some TTC patients 
MMP-8 and TIMP-1 levels may explain more severe left-ventricle (LV) impairment.  
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LYHENNELMÄ 
Takotsubo kardiomyopatia (TTK) on akuutti sydänkohtaus, joka muistuttaa oireiltaan sydäninfarktia. 
Myös monet sydänfilmilöydökset, kuten ST-tason muutokset, ovat samankaltaisia. Toisin kuin 
tavallisessa sydäninfarktissa, TTK-potilailla ei todeta merkittävää sepelvaltimotautia. TTK-
potilaiden tyyppilöydös on sydänlihaksen laaja-alainen lamautuminen, joka normaalistuu 
seurannassa.  
 TTK:n ilmaantuvuus on noin 2% kaikista sydäninfarktin oirein sairaalaan päätyvistä 
potilaista. Sydäninfarktin luotettava erottaminen TTK:sta vaatii samankaltaisten ensivaiheen oireiden 
ja löydösten vuoksi sepelvaltimoiden varjoainekuvauksen. Potilaiden jatkohoito eroaa merkittävästi, 
minkä vuoksi diagnoosin pääseminen varhain on tärkeää. 
 Oireyhtymän syntymekanismi on tuntematon. Sitä esiintyy lähes yksinomaan 
vaihdevuosi-iän ylittäneillä naisilla, ja usein kohtausta edeltää akuutti stressitilanne. Monista 
teorioista todennäköisimpänä pidetään suurien katekoliamiinipitoisuuksien aiheuttamaa 
sydänlihaksen lamautumista. Myös keskeytynyttä sydäninfarktia on pidetty mahdollisena 
selityksenä. Tällöin nopeasti liukeneva sepelvaltimotukos aiheuttaisi ohimenevän sydämen 
lamautumisen, muttei olisi enää nähtävissä sepelvaltimoiden varjoainekuvauksessa. 
 Väitöskirjatyön tavoitteena oli selvittää, voidaanko TTK erottaa sydäninfarktista 
kajoamattomilla tutkimusmenetelmillä. Pyrimme myös selventämään veren hyytymisen ja 
mahdollisen keskeytyneen sydäninfarktin roolia TTK:n synnyssä. 
 Tutkimuksen aineisto sisälsi 92 TTK-potilasta. Ensimmäisessä osatyössä vertailimme 
TTK:ta ja sydäninfarktia sairastavien potilaiden akuuttivaiheen sydänfilmimuutoksia. 
Muodostamamme kriteeristö pystyi erottelemaan TTK:n sydäninfarktista 63%:n herkkyydellä ja 
93%:n tarkkuudella. Tämä tarkkuus ei kuitenkaan riitä siihen, että potilaan päivystyksellisestä 
sepelvaltimoiden varjoainekuvauksesta voitaisiin pidättäytyä ST-nousun yhteydessä. 
 Toisessa osatyössä analysoimme TKK- ja sydäninfarktipotilaiden sekä terveiden 
verrokkien veren hyytymistekijäpitoisuuksia.  Akuutin vaiheen reaktion merkkiainetasot vastasivat 
potilasryhmillä toisiaan. Verisuonitukoksissa kohoava d-dimeeripitoisuus oli TTK-potilailla samaa 
tasoa kuin verrokeilla, mutta merkittävästi matalampi kuin infarktipotilailla. Tulokset eivät tue teoriaa 
keskeytyneestä sydäninfarktista TTK:n laukaisijana. 
 Viimeisessä osatyössä vertasimme sydänlihaksen ja sepelvaltimoiden rakenteeseen 
vaikuttavien entsyymien, matriksin metalloproteinaasi 8:n (MMP-8) ja tämän estäjän (TIMP-1) 
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pitoisuuksia TTK- ja sydäninfarktipotilailla. TIMP-1 pitoisuus pystyi erottamaan TTK:n ja 
sydäninfarktin toisistaan kliinisessä käytössä olevaa Troponiini T:tä paremmin. Lisäksi havaitsimme, 
että TTK potilaiden vasemman kammion heikentynyt supistuvuus oli yhteydessä matalaan MMP-
8/TIMP-1 suhteeseen. 
 Tulokset vahvistivat aiempia käsityksiä katekoliiniamiinien tärkeästä roolista TTK:n 
synnyssä. MMP-8 ja TIMP-1 pitoisuuksien käyttöä TTK:n erotusdiagnostiikassa ja vaikeusasteen 
arvioimisessa on syytä tutkia tarkemmin. 
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1. INTRODUCTION 
History and folklore contain numerous stories of heart attack and even sudden death at moments of 
extreme emotion. The concept of dying from grief or horror is strongly embedded in our folk wisdom. 
Even the saying “scared to death” is common in our every-day lives. A weak heart presents a 
traditional explanation for such an event. In recent years, however, research has implicated a possible 
modern foe behind the old concept.  
Takotsubo cardiomyopathy (TTC) was first described in Japan 25 years ago in female 
patients after emotionally stressful situations [1]. Throughout the 1990’s, the literature mainly 
consisted of small reports [2-4]. It was not until 2001 that Tsuchihashi et al released the first larger 
study of TTC and made the condition more widely known [5]. The name takotsubo was chosen to 
describe the typical motion abnormality in the left ventricle resembling a traditional Japanese octopus 
fishing pot with its narrow neck and round bottom. Other more descriptive names were stress 
cardiomyopathy, apical ballooning syndrome, and broken-heart syndrome were used, but over the 
years, takotsubo has become established as its more unique name [6]. The European Society of 
Cardiology classifies TTC under unclassified cardiomyopathies, and the American Heart Association 
under both primary and acquired cardiomyopathies [7,8]. 
Through the 2000s an increasing amount of knowledge about this peculiar syndrome 
emerged from all over the globe [9]. To date, TTC has been described in populations both in North 
America and Europe, in various Asian countries, in Australia, as well as in South America [5,9-14]. 
TTC incidence grew steadily from 2000 due to better recognition of the syndrome and 
increasing availability of coronary angiography (CAG). Because ACS is the major differential 
diagnosis for TTC, TTC diagnosis is almost solely based on the exclusion of occlusive coronary 
disease by CAG.  TTC mimics ACS with similar symptoms and findings. Even with the current non-
invasive methods, reliable distinction of TTC from ACS remains impossible. Such methods, however, 
could potentially spare patients unnecessary medications and examinations, as well as cut medical 
costs.  
Despite vigorous efforts and increasing research data, the underlying mechanisms of 
TTC remain unknown [15-20]. The plot, however, thickens, and some pieces of the puzzle have 
started to fall in place. High levels of catecholamines, especially epinephrine, have been implicated 
in various study settings, but direct evidence of the mechanism in humans is missing. Furthermore, 
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what makes some patients susceptible to TTC under high catecholamine situation also remains 
unclear. 
TTC was considered a benign disease despite its dramatic presentation, and the patients 
usually fully recover within weeks. Even though the majority of the TTC studies report infrequent 
complications, more recently, studies show a larger proportion of patients with severe complications 
as well as substantial in-hospital mortality [21]. The in-hospital mortality of 2 to 5% appears to be on 
par with that of ACS [21-26]. Such a finding, among others, emphasizes how much still needs to be 
learned from this intriguing syndrome.  
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2. REVIEW OF THE LITERATURE 
2.1. Acute coronary syndrome 
2.1.1. Epidemiology and classification 
Coronary artery disease (CAD) remains the leading cause of mortality in developed countries. Despite 
improved treatment and better management of risk factors, CAD causes over 8 million deaths 
annually worldwide [27]. CAD mortality has decreased over recent decades; but variation between 
demographic groups exists, with slow progress occurring especially in younger women [28]. 
 CAD causes reduced oxygen supply to the myocardium. ACS manifests when the 
supply suddenly decreases beyond the point when myocardial necrosis will begin. Such a lack of 
supply usually results from rapid narrowing or blockage in a coronary artery, leading to decreased or 
complete loss of blood flow to the myocardium [29]. ACS is divided into ST-elevation and non-ST-
elevation types ACS depending on the ECG findings (Figure 3). Usually, STEMI results from 
complete blockage of a coronary artery and NSTEMI and UAP from reduced blood flow [30,31]. 
 
Figure 3  Classification of acute coronary syndrome based on ECG and troponin. ECG = 
electrocardiography, LBBB = left-bundle branch block, NSTEMI = non-ST-elevation infarction, STEMI = ST-
elevation infarction, UAP = unstable angina pectoris. 
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2.1.2. Pathophysiology and risk factors 
In atherosclerosis, which causes coronary artery disease, cholesterol, accompanied by inflammation, 
accumulates in the endothelium of the arteries. This accumulation leads to formation of 
atherosclerotic plaques, consisting of a lipid core and a fibrotic cap on the luminal side. This process 
leads to calcification of the vessels and disruption of their normal structure and function [32]. 
 Coronary artery thrombosis is the most common ACS cause, and thrombosis results 
from disruption of atherosclerotic plaque within coronary artery wall. The atherosclerotic plaques 
may grow inwards, toward the coronary artery vessel lumen. Such concentric plaques narrow the 
lumen and tend to cause angina symptoms during stress. Concentric plaques tend to be more stable 
due to a thick fibrotic cap and a smaller lipid core. Fibrous cap erosion, however, may provoke 
thrombosis and lead to ACS--usually, to NSTEMI or UAP [33]. 
 Atherosclerotic plaques, that grow outwards do not narrow the vessel lumen and thus 
do not cause stress-related symptoms. Such eccentric plaques tend to have thin, weak fibrous gaps 
and large lipid cores. Such plagues are more vulnerable to rupture. Rupture reveals a large amount of 
thrombotic material into the vessel lumen and provokes thrombosis. Usually such thrombosis causes 
complete blockage of the coronary and results in STEMI [32].  
 The risk for CAD and ACS consists of genetic and lifestyle-related factors [34]. High 
cholesterol, especially low-density lipoprotein, is the key risk factor for atherosclerosis development 
[35]. Other risk factors include high blood pressure, diabetes, and smoking, often accompanied by 
minimal physical activity and a vegetable-poor diet [36,37]. These risk factors both promote the 
development of atherosclerosis and increase the workload of and oxygen demand on the myocardium. 
 
2.1.3. Symptoms, diagnosis and treatment 
Symptoms include chest pain, often radiating to the left arm or neck, shortness of breath, and nausea. 
The presentation may also be vaguer with symptoms of discomfort, palpitations or gastric pain. 
Myocardial ischemia may also present with ventricular tachycardia and lead to sudden death [30,31]. 
 The initial diagnosis is based on typical symptoms, ECG, and serum troponin levels. 
When ACS is suspected, antithrombotic-, nitro-glycerine-, beta-blocking- and pain medication are 
useful. CAG confirms the diagnosis. NSTEMI and UAP patients undergo CAG within a few days 
[30]. STEMI patients require immediate CAG and subsequent percutaneous coronary intervention to 
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open the clotted artery. If CAG is unavailable, thrombolytic medication can dissolve the thrombotic 
clot in the coronary artery [31]. 
 Optimal secondary prevention of ACS patients reduces risk for further events and 
improves prognosis. Prevention requires management of risk factors as well as favorable lifestyle 
changes. Medication includes statins, angiotensin convertase enzyme inhibitors, beta-blockers, and 
antiplatelet therapy [38-40]. 
 
2.2. Takotsubo cardiomyopathy 
2.2.1. Definition 
Despite many proposed criteria for TTC, no international consensus exists [20]. We applied the 
following most commonly used modified Mayo Clinic criteria [41,42] . All four must be present for 
a TTC diagnosis: 
1. New electrocardiographic (ECG) change (ST-elevation or T-wave inversion or both) or 
cardiac-enzyme release (troponin or creatine kinase) or all of these. 
2. Transient hypo-, dys-, or akinesis of the left ventricular midsection with or without 
involvement of the apex extending over a single epicardial coronary vascular bed 
3. Absence of obstructive coronary artery disease (coronary luminal narrowing less than 50%) 
or plaque rupture confirmed by coronary angiogram (CAG) 
4. Absence of myocarditis or pheochromocytoma 
The Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of 
Cardiology further redefined the criteria by adding elevated serum natriuretic peptide [43]. Recent 
suggestion is that the contraction abnormality in pheochromocytoma represents TTC, and thus can 
classify as a physical stressor [20]. 
 
2.2.2. Pathophysiology 
2.2.2.1. Catecholamine theory 
Since the findings of Wittstein et al in 2005, TTC has been associated with high levels of circulating 
catecholamines [44]. That small study presented 2 to 3 fold higher epinephrine and norepinephrine 
levels in TTC than in matched myocardial infarction (MI) patients. TTC patients’ catecholamine 
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levels remained elevated for a follow-up period of 7 to 9 days. The metabolite levels of the 
catecholamines, metanephrine and normetanephrine, showed elevation, but did not differ from the 
MI group levels. 
Madhavan et al. in 2009 reported opposite results. They found subacute circulating 
fractioned catecholamine levels in 19 TTC patients similar to 10 age- and sex-matched STEMI 
patients. For the TTC patients, all of their metanephrine and 74% of the normetanephrine levels were 
normal. In the same study, 24-hour urine samples of fractioned catecholamines and metanephrines 
were normal in all but the two TTC patients, who had mildly elevated metanephrine levels [45].  
The most recent catecholamine study reported normal or only moderately elevated 
values in the majority of the 33 TTC patients; epinephrine was elevated in 3, norepinephrine in 13, 
metanephrine in 5, and normetanephrine in 9 patients. Sampling occurred within 1 to 7 days after 
admission. As the delay from admission to blood sampling affected the selection of blood work, not 
all samples were not available for all patients. The trigger factor or TTC localization did not influence 
the results, however; patients complicated by heart failure had higher normetanephrine levels [46]. 
The histology of TTC patients supports the catecholamine excess theory. Serial 
endomyocardial tissue samples of 8 TTC patients showed acute morphological alterations indicative 
of catecholamine excess-derived microcirculatory dysfunction and direct cardiotoxicity. Such 
transient changes disappeared by the time of the second sampling after functional recovery. No signs 
of necrosis were evident [47]. Whether the alterations affected the whole depth of the myocardium, 
and what was the severity of changes in different parts of the myocardium remains unknown. 
A high level of circulating epinephrine is thought to activate a cardio-protective 
mechanism in the myocytes [48]. Under normal conditions, coupling of epinephrine to beta-
adrenergic receptor (BAR) activates the stimulating GalphaS. GalphaS promotes the action of adenylate 
cyclase, which produces cyclic AMP (cAMP). The elevated concentration of cAMP leads to 
activation of protein kinase A (PKA). The activation opens the L-type Ca2+ -channels leading to 
muscle contraction. G-protein receptor kinase 5 controls the activation of BAR by phosphorylation 
followed by coupling to arrestin. Arrestin inactivates the BAR and promotes its internalization from 
the cell membrane. Under high circulating epinephrine concentrations, however, the binding of 
epinephrine leads to activation of GalphaI, which prevents the cAMP production and shuts down the 
signaling [49].  
The possible mechanism behind TTC was described in a rat model, where a TTC-like 
contraction abnormality could be triggered with a high-dose intravenous epinephrine bolus, but not 
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with norepinephrine. The effect of such an epinephrine bolus could be inhibited by pre-treatment with 
pertussis toxin, an inactivator of GalphaI [50]. Whether such a finding applies to humans is unknown. 
 
2.2.2.2. Aborted MI or microvascular thrombosis 
Aborted MI results from the spontaneous dissolving of a coronary thrombosis. The lack of oxygen in 
the ischemic region may cause a temporary abnormality in myocardial contraction described as 
stunning. Some studies have suggested such a thrombotic mechanism to be responsible for TTC 
[51,52]. Hypothetically, aborted MI in a long wrapping left anterior descending coronary vessel could 
cause a apical stunning similar to that seen in the TTC. An acute fast-dissolving thrombus, especially 
from coronary artery wall erosion, could be missed by CAG. Such thrombi are the cause of occlusion 
in 30 to 35% of ACS patients [53].  
Coronary artery wall structures can be visualized by two catheter-based imaging 
modalities. Intravascular ultrasound (IVUS) uses soundwaves to assess possible disruptions in artery 
walls. Due to insufficient resolution, however, the intravascular ultrasound may also miss a thrombus 
on top of an area of vessel erosion [54]. One IVUS study showed a ruptured atherosclerotic plaque in 
the left anterior descending coronary artery of 5 TTC patients [52], but another showed no signs of 
plaque rupture or thrombi in 10 TTC patients [54]. Optical coherence tomography (OCT) is an optical 
based method otherwise like intravascular ultrasound, but with up to 10-fold resolution. At the 
moment, it is the most reliable method for finding changes in the coronary artery walls such as 
coronary erosion [33]. Only one case report of TTC and OCT exists, and the results showed no signs 
of erosion, plaque rupture, positive remodeling, or thrombi in the LAD vessel [55]. 
Supportive evidence for the aborted MI theory behind TTC came from a study 
comparing ECGs of 20 TTC, 20 spontaneous LAD-reperfusion, and 20 mechanically reperfused LAD 
MI patients. ECGs recorded from hospital admission up to 6 days of hospitalization showed similar 
results between the TTC- and aborted MI groups. TTC patients differed from the mechanically 
reperfused group in T-wave voltage and QT-interval length [56]. 
Widespread microcirculatory thrombosis beyond single-vessel territory could in theory 
cause broad myocardial stunning, despite normal coronary angiography and absence of plaque 
rupture. The role of microvascular dysfunction in TTC pathogenesis has been debated and evaluated 
by Doppler guide wire, TIMI frame count and myocardial perfusion grade, nuclear imaging, and 
contrast echocardiography [41,57-60]. The results show impaired perfusion, which normalizes in 
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follow-up after 3 to 4 weeks [58,59]. In the affected myocardium, Yoshida et al. (2007) reported 
extensive metabolic defects exceeding the volume of the perfusion defect. This result favors a 
metabolic origin for the microvascular dysfunction as opposed to a thrombotic origin [60]. Whether 
microvascular dysfunction is the cause or is secondary to TTC remains unknown. 
 
2.2.2.3. Coronary spasm 
Early reports proposed the coronary spasm as the underlying mechanism for TTC since in the CAG 
no obstruction of the coronaries was apparent. The fact that the contraction abnormality involves an 
area larger than provided by a single coronary artery and that the unlikeliness of multivessel coronary 
spasm presented later questions as to this hypothesis. 
 Reports of coronary spasm provocation tests with ergovine and acetylcholine show an 
incidence of provoked spasms ranging from 0 to 71%. Altogether 7 studies comprised 112 patients. 
Coronary vessel spasm was provoked in 30% of the patients and multivessel spasm in 10% (Table 1) 
[15]. Only 3 patients exhibited spontaneous spasm during CAG. These researchers performed 
provocation tests in either the acute or chronic phase, which may have affected results. 
 
Table 1 Results of coronary-spasm provocation test reports [5,61-66] 
Reference Provocative test Method 
Abe 2003 14% (1) ach 
Akashi 2005 0% (0) ach 
Athanasiadis 2006 59% (10) ach 
Kawai 2000 29% (2) N/A 
Kurisu 2002 71% (single 4 / multi 6) ach 12 / erg 2 
Sato 2006 0% (0) erg 
Tsuchihashi 2001 21% (single 5 / multi 5) ach 
      
ach = acethylcholine, erg = erovine, multi = multivessel, single = single 
vessel 
% (n)     
 
A small endomyocardial biopsy series revealed endothelial cell apoptosis in conjunction with reduced 
perfusion [67]. Another small study showed increase in peripherally measured vasoconstriction and 
endothelial dysfunction during a mental stress test in follow-up TTC patients compared to controls 
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[68]. These data suggest that TTC may be accompanied by an impaired endothelial function related 
to endothelial cell damage causing microvascular spasm. 
If a coronary or microvascular spasm plays a role in the pathogenesis of the TTC, it 
may require other co-existing factors to emerge in the acute phase. Alternatively, the spasm could be 
a contributing factor in some TTC patients. 
 
2.2.3. Epidemiology 
TTC comprises 2 to 2.5% of patients with symptoms and findings of ACS. Because 90% of TTC 
patients are women, most of the peri- or post-menopausal, the incidence in that particular 
population is up to 6% [69]. Even though initially reported in Japan, TTC cases occur worldwide 
with the highest number per capita in Europe [9]. 
  
2.2.4. Triggers 
Acute emotional stress precedes TTC in roughly one third of all patients. According to same review, 
commonly reported stressors include news of death or serious illness of a family member or a friend 
or a frightful situation e.g. being a victim of a mugging. Third of the patients have a physical stressor, 
which can be either physically strenuous situation such as unusual exercise or non-cardiac co-
morbidity like subarachnoid hemorrhage or cancer. A distinct acute stress-factor is missing from the 
remaining third of the patients, and some patients report only prolonged mental stress or fatigue. Men 
have high rate of preceding physical stress or another medical condition, whereas women tend to have 
emotional stress or no stressor at all [70]. 
The incidence of stress factors varies among reports [5,11,12,20,71]. More appropriately, TTC 
can be divided into primary and secondary depending on whether the TTC is the primary reason for 
hospitalization [43]. TTC case reports feature various distinct stressors such as therapeutic and 
accidental intravenous epinephrine injections [72-74]. And several reports also contemplate the role 
of insect, spider, snake, and jellyfish bites or stings [75-82], but whether any venom or the stressful 
situation itself triggers TTC, remains unknown. Interestingly, TTC incidence rises after natural 
disasters such as earthquakes [83-85]. 
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2.2.5. Presentation 
TTC is an acute cardiac condition with symptoms resembling those of the ACS. Besides 90% of the 
patients’ being women, [70] of an average age of 67 years, reported cases range from 16 months to 
98 years [71,86,87]. Chest pain is the most common symptom in 75.9% followed by dyspnea in 
46.9% and fainting in 7.7% [71]. Other symptoms have been reported in smaller numbers such as 
nausea or vomiting, and fatigue [11,12,71]. The presentation depends on the severity of the 
symptoms, which may range from mild discomfort to cardiogenic shock. TTC incidence is highest in 
the afternoon and during summertime [22,88]. 
 
2.2.6. Variants 
The early reports defined TTC as an apical ballooning syndrome. The classical form comprised 
hyper-contractile basal part and a- or dyskinetic apical and mid-ventricular part of the left ventricle. 
After Hurst et. al. published the first case with mid-ventricular TTC in 2006, recognition of atypical 
forms increased [89]. Currently overall of 5 different types other than apical have been reported in 
18-40% of the TTC patients [12,90-92]. The etiology of different TTC patterns remains unknown and 
recurring cases may have a different pattern than initial event [93,94]. Right-ventricle involvement 
appears in roughly one third of the patients and usually accompanies worse LV function and a higher 
complication rate [90,95]. 
 
2.2.7. Diagnosis 
2.2.7.1. Electrocardiography 
ECG findings in TTC and in ACS have a high resemblance. In the TTC patients, ST-elevation and 
T-wave inversion are the most common findings in approximately 70% of patients. Third of the 
patients exhibit abnormal Q-waves [96], and the evolution of the ECG changes are similar in TTC 
and ACS: the resolution of the ST-elevation followed by development or deepening of T-waves or 
both [51]. ECG in TTC normalizes during the follow-up. Electrophysiological changes on a cellular 
level in TTC are unknown. 
ST-elevation myocardial infarction (STEMI) requires fast decision-making and 
immediate revascularization. By many ECG-based criteria, studies have tried to differentiate TTC 
from STEMI in order to help in the assessment of necessary procedures and care. The studies used 
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ST-segment and T-wave changes, Q-waves, QT-interval measurements, and QRS morphology 
[56,97-106]. The results were controversial and due to insufficient sensitivity and specificity, most 
researchers would not recommend to their clinical use.  
Kosuge et al. suggested (2010), for the differentiation of TTC from STEMI, the lack of 
ST-elevation in V1 and ST-depression in aVR. This criterion has the highest specificity and sensitivity 
to date (91% and 96%, respectively) [98]. Another study used ST-elevation amplitude <1.75mm in 
V2 and < 2.5mm in V3 for the differentiation, with sensitivity of 67% and specificity of 94% [107]. 
This procedure was replicated in another study providing a sensitivity of 79% and specificity of 73%, 
while other criteria offered less impressive results than in the many original publications [108]. The 
studies are difficult to compare, because some studies use measurement criteria differing from the 
guidelines [31], like J-point + 0.08s for the ST-elevation [56,98,99,104]. The differing measurement 
method may result higher amplitudes and differing sensitivities and specificities.  
Negative T-wave results show higher variation than does the ST-segment; the incidence 
of negative T-waves ranges on admission from 17% to 71% [99,103,109]. Such controversy suggests 
the current ECG studies may offer an unreliable picture of the T-wave changes. Moreover, one of the 
studies did not even report negative T-waves [98].  
The time from symptom onset to ECG ranges between the studies from 3.4 ± 2.0 to 11.0 
± 8.6 hours [97,98,100,110], while some studies report only the usage of on-admission ECGs without 
any specific time-interval [56,99,101,103,105]. Serial ECGs from TTC patients revealed an evolution 
from acute phase ST-elevation to T-wave inversion in the subacute phase; therefore, the variability 
of the ECG changes on admission may have resulted from different time-intervals from symptom 
onset to ECG [56]. Dib et. al. (2009) compared the time-interval from symptom onset to ECG based 
on the primary ECG finding: ST-elevation, T-wave inversion or non-specific ST-T-changes [104]). 
The groups had a similar time delay from the beginning of the symptoms to ECG, which suggests the 
primary ECG finding is not solely time-dependent [104]. 
Despite the variable amount of impaired left ventricle (LV) in the mid-ventricular TTC, 
the ECG changes remain few. Even the more severe cases show ST-elevation in leads I, aVL and V2-
4 only [105]. ECG, however, records the mid-ventricular area of the myocardium inaccurately. The 
area is only recorded horizontally by lead V2 and in frontal plane by leads I and aVL while the apical 
part is much better represented by the chest leads. 
The absence of abnormal Q-waves has been proposed to favor a TTC diagnosis over 
ACS due to the lack of necrosis in TTC [99]. A later study, however, reported one third of TTC 
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patients to have Q-waves despite no signs of necrosis by magnetic resonance imaging (MRI). Most 
commonly, Q-waves were in leads V2-3, but no specific information existed as to morphology or of 
the leads affected. [101]. 
A common finding in TTC is QT-interval prolongation. Its incidence ranges from 50 to 
100%, but in TTC torsades de pointes is rare[111]. Arrhythmias, in general, are not uncommon: atrial 
fibrillation appears in 5 to 15%, ventricular arrhythmias in 4 to 9% and cardiac arrest in 4 to 6% of 
the patients [112-114]. Risk for life-threatening arrhythmias associates with male sex [113]. 
 
2.2.8. Treatment, recurrence and prognosis 
TTC has no specific treatment, but standard heart-failure treatment applies [115]. No medications 
have proven universally useful in prevention of recurrence [116], though ACE-inhibitors/angiotensin-
receptor blockers may reduce recurrence [117]. The annual recurrence rate is 1 to 2 % [117]. 
 Previously, TTC was considered as a benign disease. Recently Singh et. al. (2014), 
however, reported initial hospitalization mortality as high as 4.5% similar to that of a STEMI. Factors 
associated with mortality included secondary TTC and male sex [21]. Sharkey et. al. (2015) 
discovered that 20% of TTC patients, who were hemodynamically unstable on admission, had a 
higher risk for complications. Out of these patients 20% died during the initial hospital stay [118]. 
 
2.3. Cardiac catheterization 
First coronary angiography was performed in the late 1950s [119]. Nowadays, CAG is routine in the 
diagnosis of acute coronary syndrome, and coronary intervention via angioplasty is the primary 
treatment when applicable. The function of the LV can be assessed in the same session as left 
ventriculography (LVG). 
The introduction of emergency CAG in clinical practice improved the diagnostics of 
ACS and led to discovery of new entities like TTC. Because TTC patients present symptoms and 
non-invasive findings similar to ACS patients, the differential diagnosis is based on the CAG. The 
CAG of TTC reveals no obstructive coronary artery disease, but the LVG shows a wide contraction 
abnormality composed of the mid-ventricular part with or without the involvement of the apical part. 
A hypercontractile basal part usually accompanies the contraction abnormality [20]. Patients with 
>50% stenosis in their coronary arteries, but with their contraction abnormality out of proportion to 
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the coronary status, may be considered having TTC especially if cardiac MRI shows no ischemic 
damage [120]. 
Unless CAG is performed in the acute phase, a TTC patient with ST-elevation, would 
be treated within the guidelines for ST-elevation myocardial infarction (STEMI). If a patient receives 
thrombolytic therapy, no TTC diagnosis can occur afterwards due to possibility of a dissolved 
atherothrombotic infarction (aborted MI). Therefore, in the diagnosis of TTC, the role of emergency 
CAG is pivotal. 
 
2.4. Biochemistry 
ACS diagnosis relies on history, ECG, and cardiac enzymes. For many decades, the improvement in 
accuracy of MI diagnostics is attributed to the development of myocardium-specific enzyme assays. 
First the creatine kinase MB-isoform, and then the troponins have allowed swift and reliable 
recognition of myocardial damage [121,122]. Elevated cardiac enzyme levels are apparent in various 
cardiac situations such as myocarditis and myocardial infarction. On admission cardiac enzyme levels 
in TTC are similar to ACS levels, and like the ECG changes, are unable to distinguish between acute 
TTC and ACS [45].  
During congestive heart failure, cardiac myocytes produce brain natriuretic peptide 
(BNP) and its precursor pro-peptide (pro-BNP). In TTC, their levels are also elevated and correlate 
with severity of the LV dysfunction and are higher than in ACS patients. The ratio of BNP to either 
troponin or creatine kinase showed the potential to distinguish between TTC and ACS [45,123]. 
Many acute conditions exhibit elevated C-reactive protein (CRP) levels, and TTC is no 
exception. CRP is an acute-phase protein synthetized by hepatocytes during inflammation and 
infection. On admission, TTC patients’ CRP levels are elevated and correlate with BNP and 
normetanephrine levels. Such findings suggest that inflammation plays a role in the pathophysiology 
of TTC [124,125]. 
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2.5. Blood coagulation 
The circulation is a closed system providing oxygen and nutrients to tissues. Damage to this system 
leads to disruption of the function and may have catastrophic consequences. An elaborate coagulation 
system reacts swiftly by forming a blood clot at the site of damage, a process called thrombosis. The 
resultant hemostasis allows repair of the underlying vascular damage and return of normal function. 
Dysfunction in the coagulation system may lead to bleeding disorders or excessive 
thrombosis. Thrombosis is an intricate interplay between circulating coagulation factors, 
thrombocytes, and the structure of the blood vessel. Damage to the vessel wall releases tissue factor 
and reveals thrombogenic material such as collagen. Endothelial cells at the site release von 
Willebrand factor (vWF), which attracts and activates circulating thrombocytes (Figure 1 and 2). 
Release of tissue factor from the endothelium activates the coagulation cascade, leading to formation 
of crosslinked fibrin. Activated thrombocytes aggregate to the site of injury and the fibrin formation 
stabilizes the plaque [126]. 
Many pathologies such as cancers and inflammatory diseases predispose to thrombosis. 
Atherosclerosis is characterized by inflamed calcified lipid plaques in artery walls and accompanies 
a thrombogenic state. Coronary artery disease is marked by atherosclerotic plaques in the coronary 
circulation. Rupture of such a plaque leads to revelation of thrombogenic material and subsequent 
formation of an intracoronary thrombus. This thrombus disrupts the coronary blood flow and results 
in ACS. 
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Figure 1. Thrombocyte activation and aggregation in the arterial damage site. The green boxes indicate 
the relevant molecules. GP = glycoprotein, sGPV = soluble glycoprotein V, vWF = von Willebrand factor. 
(Illustration by the author) 
 
Fibrinolysis is a reaction that is reverse to thrombosis. A specific degradation product 
of cross-linked fibrin is d-dimer. Elevated level of d-dimer indicates a hypercoagulable state and 
thrombus formation and degradation. D-dimer values are elevated in ACS patients [127,128]. In a 
small series of 15 TTC patients, D-dimer was elevated in 60% [60]. 
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Figure 2. Coagulation cascade on a thrombocyte surface. The green boxes indicate the relevant 
molecules. F = coagulation factor, PL = phospholipide, TF = tissue factor. (Illustration by the author) 
 
Activated platelets form the main component of an arterial thrombus. Elevated levels 
of soluble glycoprotein V (sGPV), a plasma marker of platelet activation, associate with MI 
[129,130]. The platelet surface glycoprotein (GP) IbIXV complex mediates initial platelet adhesion 
to subendothelial von Willebrand factor. Upon platelet activation, sGPV is proteolysed from the GP 
IbIXV complex and accumulates in plasma [131]. 
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2.5.1. Acute-phase reaction 
Acute-phase reaction, a defense reaction against toxic or infectious agents, is characterized by a 
cytokine-induced increase of acute phase proteins, such as C-reactive protein and coagulation factors 
like F VIII, von Willebrand factor, prothrombin, and fibrinogen. An acute-phase reaction is also a 
natural consequence of stress-induced myocardial damage. 
Evidence exist as to the stress hormones, epinephrine and norepinephrine, directly 
influencing the coagulation system and platelet function [132-136]. Catecholamines are especially 
known to release F VIII and von Willebrand factor from endothelial cells [137]. 
 
2.5.2. Left ventricular thrombus in TTC 
The reduced blood flow in the LV apex that is due to contraction abnormality may cause thrombus 
formation. Such thrombi are reported in 2-12% of cases and may cause stroke or other systemic 
embolism [24,138-141]. Thrombi usually develop during the subacute phase, but also report of a new 
thrombus after 14 days following nearly recovered LV function exists [142]. Risk for 
thromboembolic complications associates in women with a physical trigger, and in both sexes with 
ST-elevation and elevated C-reactive protein levels [140]. Therefore, anticoagulation should be 
considered during hospitalization and after discharge until a follow-up visit [115]. 
 
2.6. Matrix metalloproteinases 
Matrix metalloproteinases (MMP) are a family of zinc-dependent endopeptidases with the ability to 
cleave all kinds of extracellular matrix proteins and bioactive molecules. MMPs are responsible for 
extracellular matrix (ECM) turnover by degradation of structural proteins such as collagens. In 
addition to their role in degrading and repairing of the ECM, they take part in pathological processes. 
Inflammatory cells are the main source of MMPs, but smooth muscle and endothelial cells also 
secrete them [143]. 
MMPs are powerful enzymes with potent a destructive capability. Due to their power, their 
activity is tightly controlled at the transcription level and by endogenous inhibitors. Tissue inhibitors 
of MMPs (TIMP) perform a vital part in their regulation. Any imbalance between MMPs and TIMPs 
may lead to an alteration in the net proteolytic effect and disrupt normal ECM properties. In the 
myocardium, the ECM provides the scaffolding for myocyte attachment and proper alignment. 
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Furthermore, the ECM participates in signaling and contains many bioactive molecules [143]. The 
ECM affects both the form and function of the heart, which in conjunction with improper MMP and 
TIMP levels, are altered in many cardiovascular diseases (CVD) [144-146]. 
 
2.6.1. MMPs and TIMPs in ACS 
Atherosclerosis, unless interrupted, is a progressive disease marked by inflammation and dynamic 
changes in artery walls [147]. Rupture of an atherosclerotic plaque reveals thrombotic material from 
the plaque and vessel wall, which leads to thrombotic occlusion in the vessel and MI. The fibrous cap 
of the plaque separates the lipid core from the vessel lumen and contains mostly type-I collagen, 
which is mainly degraded by MMP-8, also known as neutrophil collagenase [148]. MMP-8 was 
implicated in the shoulder region of advanced inflamed atherosclerotic plaques, the areas most prone 
to rupture [149-151]. MMP-8 is specifically controlled by TIMP-1, which also has growth-factor-
like- and pro-inflammatory effects [152,153]. ACS patients show elevated serum MMP-8 and TIMP-
1 levels [144,154]. These pieces of evidence suggest that MMP-8 and TIMP-1 play roles in the 
weakening of an atherosclerotic plaque and development of ACS. 
 
2.6.2. MMPs and TIMPs in LV remodeling 
Changes in the composition, form, and function of the myocardium in a variety of heart diseases are 
collectively termed left ventricle (LV) remodeling. Changes in the ECM play a pivotal role in their 
process. Instead of a passive structure, the ECM forms an active scaffolding for myocardial cells that 
directly affects myocardial contraction. Furthermore, the ECM takes part in cellular communication 
and contains various active biomolecules [143]. 
Different etiologies like arterial hypertension and coronary artery disease cause LV 
remodeling, that causes impaired myocardial function and may ultimately lead to heart failure. Such 
changes in ECM structure in conjunction with altered MMP and TIMP levels, suggests their 
involvement in the pathogenesis [145,146]. An imbalance between MMPs and TIMPs leads to an 
increase or decrease in fibrotic ECM content depending on etiology.  
Serial endomyocardial biopsies of TTC patients show, during the acute phase, inflammatory 
cells and transient interstitial fibrosis. Biopsies after functional recovery show normalization of ECM 
fibrotic content [47,155]. Another study also measured MMP-2, MMP-9, and TIMP-3 levels from 
tissue samples. In the acute phase, MMP-9 levels were high, while others remained unchanged [155]. 
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Earlier serum MMP and TIMP profiles in 10 TTC patients showed patterns similar to those in 
hypertension and diastolic HF patients. TIMP-4 was elevated and MMP-1 and MMP-8 are low. 
TIMP-1 levels remained unchanged. That study included no direct comparison with HF or ACS 
patients [156]. The associations of the transient fibrosis, LV function, and MMP and TIMP levels 
remains unknown. 
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3. AIMS OF THE STUDY 
The studies were performed to elucidate the pathogenesis behind TTC and improve the selection of 
differential diagnostic tools between TTC and ACS. The main goals of the conducted four studies 
were to discover 
 
1) whether if TTC can be differentiated from ACS by ECG (I) 
2) the role of thrombosis in TTC pathogenesis (II) 
3) whether TTC can be differentiated from ACS by MMP-8 and TIMP-1, what is their role in 
TTC severity (III)  
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4. METHODS 
4.1. Population 
The complete TTC population comprise 92 patients. The studies included a varying number of study 
subjects depending on available data. Study sample came from from two populations.  
Population I comprised patients from the prospective Corogene study [157]. A total of 
5276 consecutive patients assigned for CAG were included in this study in Helsinki University 
Central Hospital between June 2006 and March 2008. The patients comprised 3000 elective patients 
(no coronary artery disease 1201 and stable coronary artery disease 1799) and 2276 acute patients 
(acute coronary syndrome 2090 and ACS-like presentation without coronary artery disease 204). The 
CAGs of the ACS-like patients were carefully reviewed, and 47 patients met the TTC criteria (see 
2.3). Of the ACS- and ACS-like patients, TTC incidence in the Corogene population was 2.0%. 
Patients filled in family history- and risk-factor questionnaire. Examinations were performed during 
their hospitalization. 
For Population II, a retrospective search for TTC patients was performed in the Helsinki 
University Central Hospital cardiology registry between May 2001 and June 2006, and April 2008 
and December 2009. A total of 196 possible candidates ppeared in this registry, which was in line 
with the incidence from the Corogene study. After the review of the CAG and LVG, however, only 
96 patients met TTC criteria, of whom 7 had died. The remaining patients were reached by phone, 
and 41 were willing to participate in the study. Reasons for refusal were: 22 unreachable, 14 deciding 
not to attend, 12 in too frail condition for a clinic visit. Patients attended a clinic visit during which 
they were interviewed and examined. An additional 4 prospective TTC patients were enrolled 
between January and June 2010.  
Co-morbidities, coronary risk factors, clinical characteristics, medications, trigger 
factors, and echocardiography information for left ventricle recovery assessment were acquired from 
patient records and by interview. 
All patients signed an informed consent. Study protocols were approved by the ethics 
committee of Helsinki University Central Hospital. 
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4.2. Left ventriculography 
CAG and LVG were performed in the acute or sub-acute phase for all 92 TTC patients. In TTC, the 
delay from symptom onset was 55.9 ± 49.4 h. Information on delay in ACS patients was unavailable. 
For the STEMI patients in our hospital, the average time from first medical contact to reperfusion 
was 119 minutes.  
 
 
Figure 4 On the left apical and on the right a mid-ventricular TTC during systole. 
 
The type and extent of the contraction abnormality was assessed from LVG by adapting 
a method previously described for tomographic heart imaging. The left ventricle was divided into 
three parts: the apical 30%, mid 35%, and basal 35% [158]. Four differing TTC patterns were found: 
1) broad apical (i.e. mid and apical akinesia/dyskinesia), 2) small apical, 3) symmetric mid-
ventricular, and 4) asymmetric mid-ventricular. Due to the small number of mid-ventricular TTC 
patients, apical (1,2) and mid-ventricular (3,4) types were combined before the statistical analysis 
(Figure 4). LVG was performed with the Siemens AXIOM Artis dFC system. Ejection fraction (EF), 
end diastolic volume, end systolic volume, and stroke volume were measured with Siemens AXIOM 
Sensis software (Siemens AG, Forcheim, Germany). The software was unable to perform the 
measurements for 10 patients out of the 92. 
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4.3. Electrocardiography 
For Study I, TTC and anterior-STEMI patients’ acute-phase ECG recordings (<24h from symptom 
onset) were reviewed. Such an ECG was available for 57 of the 92 TTC patients—29 from population 
I and 28 from population II. 
A random selection was performed of 96 anterior-STEMI patients with available acute 
ECG recording from the Corogene study. STEMI was defined by European Society of Cardiology 
guidelines: typical symptoms and ST-elevation ≥2 mm in men, or ≥1.5 mm in women in leads V2–
V3 or ≥1 mm in other leads or both [31]. Patients underwent acute coronary angiography with the 
following findings: a left anterior descending coronary artery occlusion (LADa, n = 43 or LADb, n = 
53); (TIMI 0 flow, n = 47) or stenosis (TIMI 1–3 flow: n = 49). All participants received percutaneous 
coronary intervention. 
Pain-onset to ECG interval was longer in apical-TTC, 7.6 ± 6.7 h, than in anterior-
STEMI patients, 4.7 ± 5.5 h. In this regard, the mid-ventricle-TTC and anterior-STEMI 10.3 ± 8.6 h 
vs 4.7 ± 5.5 h patients did not differ. The two TTC groups also had a similar delay.  
ST-segment measurements were made at the J-point, following the European Society 
of Cardiology guidelines [31]. The minimum requirements for each measured parameter were: ST-
segment elevation ≥1.0 mm, negative T-wave ≥0.5 mm, Q-wave amplitude ≥2 mm, and duration 
≥0.02 s (≥0.04 s for III-lead). 
 
We sought answers to the following questions concerning ST-elevation and negative T-waves:  
 
i. How many patients had at least one lead affected by a specific ECG change?  
ii. How frequently was each lead affected? 
iii. What was the amplitude of one specific ECG change?  
 Abnormal Q-waves were defined as length ≥0.02 s (≥0.04 s for III-lead) and amplitude 
>2mm. Both QT-interval length as well as incidence of prolongation were compared. A linear 
regression model described by Sagie et al. serve to adjust the QT-interval to a heart rate of 60 beats 
per minute [159]. QT-interval length of over 440 ms was defined as prolonged. QT-interval was 
measured from lead V4. 
 One physician (O.P.) analyzed all the ECGs in random order. For the most important 
ECG variables, the ST-elevation and negative T-wave amplitude, 20 randomly selected ECG’s were 
re-analyzed, which yielded an intra-observer variability of 1.9%. 
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4.4. Biochemistry 
Cardiac enzyme levels on admission and the highest values during hospitalization were collected: 
Troponin T (TnT) from 86, Troponin I (TnI) from 5, and CK-MBm from 7 TTC patients. 
The available N-terminal prohormone of brain natriuretic peptide level was collected. Blood 
sampling was performed following the laboratory standards of the Helsinki University Central 
Hospital. 
Population I patients were enrolled in Studies II and III. The blood samples were drawn from 
the arterial cannula in the beginning of the CAG in the catheterization laboratory. Before analysis, 
the citrated plasma was stored at – 80Cº.  
Both studies included ACS patients from the same Corogene study. The ACS definition was: 
1) episode of chest pain typical for ischemia, and > 50% stenosis in at least one coronary artery, 2) 
typical ischemic ECG changes for unstable angina (UAP), non–ST-elevation myocardial infarction 
(NSTEMI), or ST-elevation myocardial infarction (STEMI), and 3) elevated level of cardiac 
biomarkers in NSTEMI or STEMI. 
 
4.4.1. Coagulation studies (II) 
Equal numbers of age- and sex matched ACS patients, and patients without coronary artery disease 
(No-CAD) were selected from the same Corogene study. Overall this was 6 UAP, 29 NSTEMI, and 
12 STEMI patients. Blood sampling was similar to that of TTC patients.  
All ACS and TTC patients were on standard antiplatelet and anticoagulation medication. CAG 
was conducted in all TTC and ACS patients during the acute phase (median 48 hours, (IQR 24 – 96) 
vs. median 48 hours, (IQR 24 – 90); p = 0.94), respectively. Coronary intervention was performed 
when applicable [30,31]. The no-CAD patients were scheduled for elective CAG due to chest pain, 
valve problems, or cardiomyopathy 
We measured fibrinogen (Fg) (STA®-Fibrinogen 5, Diagnostica Stago, Asnieres sur Seine 
France), Thrombin-antithrombin complex (TAT) (Enzygnost® TAT micro, Siemens Healthcare 
Diagnostics Products GmbH, Marburg, Germany),  D-dimer (Asserachrom® D-Di, Diagnostica 
Stago), soluble glycoprotein V (sGPV) (Asserachrom® Soluble GPV, Diagnostica Stago), and 
vonWillebrand factor –antigen (vWF:ag) (STA-Liatest® vWF:Ag –reagent, Diagnostica Stago), 
high-sensitivity C-reactive protein (hsCRP) (Orion Diagnostica, Espoo, Finland) from the same 
arterial sample.  
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4.4.2. Matrix metalloproteinases (III) 
In addition to TTC population I, 2072 ACS patients were enrolled from the Corogene study: 722 
STEMI, 1123 NSTEMI, and 226 UAP. The same blood samples were used as in Study II. 
Controls were, 1000 subjects from the 1997 population-based health-survey FINRISK [160]. 
These subjects were free of cardiovascular diseases during their 13-year follow-up. Blood samples of 
the controls were drawn during a clinic visit at the Disease Risk Unit in the National Institute for 
Health and Welfare, Helsinki [161]. The FINRISK study was approved by the ethics committee of 
the National Public Health Institute. All patients gave their written informed consent. 
Time-resolved immunofluorometric assay (IFMA) and enzyme-linked immunosorbent assay 
(ELISA; R&D Systems, Minneapolis MN, USA) served to determine the serum MMP-8 and TIMP-
1 concentrations from all study participants [162]. 
  
 
4.5. Statistical analyses 
Statistical analyses were performed with SPSS 16.0, 21.0 and 22.0 (SPSS Inc., Chicago IL, USA). 
Significance of the differences in the quantitative variables between cases and controls, and within 
TTC patients were analyzed depending on the normality and size of the study groups by Student’s t-
test or the Mann-Whitney U-test. When applicable, non-parametric variables were log-transformed 
before analysis. Categorical variables were analyzed either with the chi-square or Fisher exact test. 
Relations between variables were separately tested with Pearson correlation or Spearman’s rho for 
cases and controls. A p-value less than 0.05 was considered statistically significant. 
Receiver-operating characteristics (ROC) served in assessment of the diagnostic ability of the 
MMP-8, TIMP-1 and MMP-8/TIMP-1 ratio to distinguish cases from controls. C-statistics assessed 
whether such determinations had any value over the traditional risk factors. Associations between the 
tertiles of the determined concentrations and diagnoses were analyzed with an adjusted multivariate 
logistic model. All parametric values are given as mean ± standard deviation (SD) and non-parametric 
as median (interquartile range (IQR)). A p-value < 0.05 was considered statistically significant.  
  
 36 
5. RESULTS 
5.1. Clinical features 
A female dominance of 91.3% was evident, as expected, and patients were mostly post-menopausal 
(66 years ± 10). Chest pain (81.5%) was the main symptom on admission, whereas 19.6% reported 
dyspnea and 2.2% nausea. Thorax X-rays of 34 patients of the available 78 showed excessive 
plethoricity (15.4%), congestion (26.9%), or pleural effusion (5.1%). Eight patients received non-
invasive ventilation (continuous positive airway pressure or bi-level positive airway pressure 
ventilation) and 7 inotropic medications. Treatment of 2 patients required intubation and mechanical 
ventilation. No intra-aortic balloon pumps were necessary (Table 2).  
Classic cardiovascular risk factors were as follows: hypercholesterolemia (total 
cholesterol >5 or low-density lipoprotein >3) (45; 48.9%), diabetes (14; 15.2%), hypertension (47; 
51.1%), and smoking: current (18; 19.6%), ex-smoker (25; 27.2%). History of coronary disease in 
the family was present in 39.1% of the patients, but none reported confirmed cases of TTC within the 
family. All patients survived their initial hospitalization (Table 2). 
Of the 21 patients who used beta-blocking drugs daily, 12 took beta-1-selective and 9 
non-selective beta-blockers. In addition, 4 had a prescription for propranolol occasional use due to 
rhythm disturbances or anxieties. A total of 22.8% of patients were taking beta-blockers at the time 
of TTC onset, which suggested the limited power of beta-blockers in TTC prevention. Other 
medications are described in Table 1. Statin use was higher in population I than II probably due to 
increasing overall usage during the 2000s (Table 2). 
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Table 2. Demographics of both TTC populations, adapted from Parkkonen et. al. 2014 with publishers 
 permission (I). 
 
Valid 
cases 
All TTC          
(n = 92) 
Population I 
(Corogene)        
(n = 47) 
Population II      
(n = 45) 
p-value 
      
Age, years, mean ( ±  SD) 92 65 (± 10) 66 (± 9) 64 (± 11) 0.237 
Female 92 84 (91.3) 42 (89.4) 42 (93.3) 0.499 
Family history (MCC) 92 36 (39.1) 19 (40.4) 17 (37.8) 0.795 
Prior medications 
     
Regular??-blocker  92 22 (23.9) 11 (23.4) 11 (24.4) 0.134 
Propranolol when necessary 92 4 (4.3) 4 (8.5) 0 (0.0) 0.134 
?-sympathomimetic (long-term)? 92 7 (7.6) 1 (2.1) 6 (13.3) 0.043 
?-sympathomimetic (short-term)? 92 6 (6.5) 3 (6.4) 3 (6.7) 0.956 
Atrodual near TTC 92 6 (6.5) 5 (10.6) 1 (2.2) 0.102 
ACE-inhibitor 92 22 (23.9) 14 (29.8) 8 (17.8) 0.177 
AT-blocker 92 12 (13.0) 7 (14.9) 5 (11.1) 0.590 
Calcium channel blocker 92 4 (4.3) 3 (6.4) 1 (2.2) 0.328 
Diuretic 92 25 (27.2) 15 (31.9) 10 (22.2) 0.296 
Metformin 92 9 (9.8) 4 (8.5) 5 (11.1) 0.675 
Insulin 92 3 (3.3) 2 (4.3) 1 (2.2) 0.583 
Statin 92 36 (39.1) 26 (55.3) 10 (22.2) 0.001 
Co-foundings 
     
FA 92 9 (9.8) 8 (17.0) 1 (2.2) 0.017 
TIA 92 1 (1.1) 0 (0.0) 1 (2.2) 0.304 
DM; n (%) 92 14 (15.2) 8 (17.0) 6 (13.3) 0.514 
Hypertension 92 47 (51.1) 25 (53.2) 21 (46.7) 0.532 
Hypercholesterolemia 92 45 (48.9) 23 (48.9) 22 (48.9) 0.996 
Asthma 92 9 (9.8) 4 (8.5) 5 (11.1) 0.675 
COPD 92 3 (3.3) 2 (4.3) 1 (2.2) 0.583 
Thorax X-ray 
     
Normal 80 45 (56.3) 21 (50.0) 24 (63.2) 0.491 
Excessive plethoricity 80 12 (15.0) 7 (16.7) 5 (13.2) 0.491 
Congestion 80 23 (28.7) 14 (33.3) 9 (23.7) 0.491 
Treatment 
     
Time to therapy (h) (from onset of the pain) 91 56 (± 49) 58 (± 44) 53 (± 55) 0.633 
Sympathomimetics / Inotropics 92 8 (8.7) 3 (6.4) 5 (11.1) 0.421 
Non-invasive ventilation 92 8 (8.7) 5 (10.6) 3 (6.7) 0.286 
Intubation 92 2 (2.2) 2 (4.3) 0 (0.0) 0.286 
LV - Cineangiography 
     
EDV (ml) 82 102.9 (± 23.9) 104.1 (± 26.0) 101.4 (± 20.6) 0.609 
ESV (ml) 82 49.9 (± 20.2) 52.6 (± 22.1) 46.6 (± 17.4) 0.179 
SV (ml) 82 53.0 (± 18.1) 51.5 (± 18.0) 54.9 (± 18.3) 0.410 
EF (%) 82 52 (± 15) 50 (± 16) 54 (± 13) 0.240 
ECHO - Cardiography 
     
EF (%) (admission) 42 44 (± 12) 42 (± 13) 46 (± 11) 0.224 
Normalized (days) 58 47.7 (± 40.4) 51.5 (± 42.1) 43.8 (± 39.0) 0.472 
      
Data are expressed as n (%) or mean ± SD. 
ACE = angiotensin-converting enzyme; AT = angiotensin; COPD = chronic obstructive pulmonary 
disease; DM = diabetes mellitus; EF = ejection fraction; EDV = end diastolic volume; ESV = end-
systolic volume; FA = atrial fibrillation; MCC = morbus coronarius cordis; SV = stroke volume; TIA 
= transient ischaemic attack; TTC, Takotsubo cardiomyopathy 
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5.2. Trigger factors 
Triggering factors we divided into three categories; emotional, physical, and no acute trigger. A 
preceding emotional stressor accounted for 55.5% of the events; the most common reasons were news 
of a death or an acute medical condition of a family member or friend. Heavy physical exertion 
preceded it in 7.6% and another non-cardiac medical condition in 12.0% of the patients. No recent 
cerebrovascular event or head trauma occurred, but one patient had a migraine attack and another an 
epileptic seizure. Patients’ meticulous interview did not identify an acute trigger in 25% of the 
patients. Table 3 describes the stressors in detail. 
Inhaled beta-agonist medication was routinely used by 14.1%: short-acting (such as 
salbutamol) 6.5% and long-acting (such as salmeterol) 7.6%. Salbutamol was administered to 7.6% 
on admission for dyspnoea. Physical trigger factors and use of beta-agonist drugs showed no 
relationship. One suspected iatrogenic TTC event followed possible intravenous administration of 
adrenaline including lidocaine for local anesthetic. 
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Table 3. Trigger factors among TTC patients 
 
  
Emotional (51 patients) Physical (18 patients) 
     
Anxiety/fear/panic (30) Argument (9) Excercise/physical activity (7) 
Anxiety attack in sauna Argument Dancing at son’s birthday party  
Being mugged Argument with nurse after cancer surgery Climbing stairs 
Experience of sexual harassment Fight with a tenant Dusting a carpet 
Car accident (no physical trauma) Fight with husband Fall from pier into ice cold water 
Change of job Fight with a customer Heavy woodwork 
Fear of upcoming surgery Fight with a dog seller Nordic walking excercise 
Fear of possible layoff Figth with son Physi“cally heavy” day, "a long day" 
Frustration after doctors appointment Fight with siblings   
Insomnia Heated conversation Non-cardiac medical condition (11) 
Threat with an axe and a crossbow  Infection/allergic reaction (4) 
News of husband’s illness Death of a close person (12) Local anesthetic with adrenaline 
Nervousness due to occupied restroom Death of a friend (3 patients) Heavy flu 
News of sister’s cerebral hemorrhage Death of a mother Stung by wasp; allergic to wasps’ 
News of daughter's divorce Death of a husband (4 patients) Traveler’s diarrhea 
News of father’s illness and daughter’s 
pregnancy 
Death of a cousin                                   
Death of a daughter Central nervous system-related (2) 
Overwhelming emotion Mother's funeral Epileptic seizure 
Overwhelming d’isappointment Son's funeral Migraine attack 
Relapse of an alcoholic husband     
Recollection of recently drowned father 
while diving   Cardiorespiratory related (2) 
Shock over husband's chest pain   Acute exacerbation of COPD 
Stressful period in life   Electrical cardioversion a week earlier 
Stress over hosting an event   Post-surgical (1) 
Stress over moving   After hip surgery 
Stress over daughter's moving   Other (2) 
Uncertainty over employment   Alcohol abuse, 3-month binge 
Unpleasant news at work place   Painful leg cramps 
Witnessing a fire at home     
Witnessing a bicycle accident     
Worry in family (2 patients)     
      
      
* 23 patients had no acute trigger    
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5.3. Left ventriculography 
Four TTC patterns emerged from the LVG analysis. The classic broad apical (77.2%) was the most 
common, and only a few small apical types (3.3%) appeared. Symmetric mid-ventricular (12.0%) 
and asymmetric mid-ventricular (7.6%) types were frequent. For further analyses, due to the small 
number of cases in most of the subtypes, the apical and mid-ventricular subtypes were combined. 
Contraction abnormality type was unrelated to medication, presenting symptoms, coronary risk 
factors, sex, trigger factors, cardiac enzymes, or thorax roentgenogram. Intraventricular thrombus 
was absent in all LVG’s. 
The mean EF was 51 ± 15%. EF and stroke volume were higher in mid-ventricular than 
apical-TTC patients (62 ± 10% vs 49 ± 15%; p=0.03, and 67 ± 23 ml vs 50 ± 18 ml; p=0.04; 
respectively). Angiotensin-II receptor-blocker users’ stroke volume (SV) was higher than non-users’ 
(66.1 ± 23.5 ml vs 50.4 ± 17.5 ml; p=0.04), however, angiotensin-convertase blockage affected no 
other results. Other medications showed no relation to LVG measurements. The measurement of 2-
dimensional LVG resulted in an EF of 0% for one patient, which suggested a contraction movement 
directed only towards the angle of view. 
 
5.4. Electrocardiography 
Acute 12-lead electrocardiography (ECG) was available for 57 TTC patients. Analysis showed ST-
elevation in 72%, negative T-wave 68% or q-wave in 37%, or both in at least one ECG-lead. 
Incidence of QT-interval prolongation was 49%. Naturally all anterior-STEMI patients had ST-
elevation present; negative T-waves apparent in 44% and q-waves in 38%. QT-interval was prolonged 
in 13%. Atrial fibrillation occurred in 2 patients. Both frequencies and amplitudes of ST-elevations 
and negative T-waves are shown in Figure 5. 
Apical and mid-ventricular TTC did not differ in ST-elevation incidence (75% vs 56%, 
p=0.23). ST-elevations occurred more frequently, and the amplitudes were higher in anterior-STEMI 
than in TTC patients in leads V1 to V5 (Figure 5). ST-elevation distribution between ECG leads 
showed similarities between anterior-STEMI and TTC except for lead V1. In mid-ventricular-TTC, 
the few ST-elevation changes were small and presented only in leads I and/or V2. In both TTC types, 
ST-elevation frequency was low in lead V1. Different TIMI flow grades did not significantly change 
the amplitude or frequency of ST-elevation or negative T-waves in STEMI ECGs. Interestingly, the 
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ECG criteria for STEMI were not obvious in any of the mid-ventricular or in 25 of the apical-TTC 
patients. ST-depression occurred only in lead aVR of 3 apical-TTC patients. 
   
 
Figure 5. (A) ST-elevation and (B) negative T-wave frequencies in percentages. (C) ST-elevation and (D) 
negative T-wave mean amplitudes in millimeters (mm). I = Apical vs. Mid-ventricular, p value; II = Apical vs. 
STEMI, p value; III = Mid-ventricular vs. STEMI, p value. STEMI = anterior STEMI. Adapted from Parkkonen 
et. al. 2014 with publisher’s permission (I). 
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Of the 3 groups on admission, the apical-TTC patients had the most frequent and highest 
negative T-wave amplitudes occurring in leads I, II, and V2 to V6. Negative T-wave featured in all 
mid-ventricular-TTC patients in at least one lead, but the amplitudes were mostly small—the more 
prominent showing in lead aVL. The negative T-wave frequency in lead aVL was higher in both 
apical- and mid-ventricular-TTC than in anterior-STEMI patients (p=0.046 vs p=0.016; respectively). 
Such finding, however, identified TTC with only 30% sensitivity and 86% specificity with 57% 
predictive value. 
Neither Q-wave incidence, QRS duration, nor axis differed between TTC groups and anterior-
STEMI (Table 4) 
 
Table 4. QRS duration and axis degree, Q-wave incidence. STEMI, ST-elevation myocardial infarction 
        
  Apical Mid-ventricular Anterior-STEMI I III III 
              
QRS duration, ms 88.2 ± 11.3 93.2 ± 11.1  90.6 ± 15.4 0.35 0.23 0.62 
QRS axis, ° 90.6 ± 15.4 12.2 ± 61.6  18.1 ± 57.9 0.82 0.84 0.77 
Q-wave, n (%) 17 (35) 4 (44) 36 (38) 0.71 0.86 0.73 
              
STEMI, ST-elevation myocardial infarction 
I = Apical vs. Mid-ventricular, p-value; II = Apical vs. Anterior-STEMI, p-value; III = Mid-ventricular vs. 
Anterior-STEMI, p-value 
  
Corrected QT-intervals were longer in apical-TTC (0.439 ± 0.046 ms) and mid-ventricle-TTC 
(0.430 ± 0.032 ms) than in anterior-STEMI patients (0.405 ± 0.042 ms) (p<0.0001 and p=0.04; 
respectively). The TTC groups did not differ in this regard. Prolonged QT-interval occurred in 13% 
anterior-STEMI, 49% apical-TTC, and 56% mid-ventricular-TTC patients. The difference between 
TTC groups and STEMI was significant (p<0.001), but not between TTC groups.  
Of the patients with ST-elevation, the lack of ST-elevation in lead V1 identified TTC with 
83% sensitivity, 70% specificity, and a predictive value of 54%. ST-elevation amplitude <2 mm in 
lead V2 identified TTC from anterior-STEMI with 73% sensitivity, 89% specificity, and 73% 
predictive value. The two combined: lack of ST-elevation in V1 and ST-elevation amplitude < 2mm 
in V2 identified TTC with 63% sensitivity and 93% specificity with a predictive value of 79%.  
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Time interval from onset of pain to ECG was longer in apical-TTC (7.6 h ± 6.7) than in 
anterior-STEMI patients (4.7 h ± 5.5). Mid-ventricle-TTC (10.3 h ± 8.6) and anterior-STEMI patients 
as well as the two TTC groups did not differ. 
 
5.5. Biochemistry 
On admission, TnT was elevated (>0.03 μg/L) in 81 patients (0.623 μg/L ± 0.927, range <0.03 to 
7.76); peak TnT release was (0.730 μg/L ± 1.317, range <0.03 to 11.91). Of the 5 patients with 
available TnI levels, 4 had elevated values (>0.3 μg/L), 0.768 μg/L ± 0.506 (range 0.26 to 1.41), and 
peak TnI release was 1.356 μg/L ± 1.313 (range 0.26 to 3.53). CK-MBm values were measured in 7 
patients, and 5 had elevated values (>9 μg/L), 14.57 μg/L ± 10.25 (range 4.0 to 29.0); peak CK-MBm 
release was 20.86 μg/L ± 24.05 (range 4.0 to 72.0). 
 Pro-BNP was available for 18 patients (median 3547 ng/L, IQR 1050 – 6029). All 
values were elevated (>300 ng/L). 
  
5.5.1. Coagulation study (II) 
The only marker of hemostasis and thrombosis that differed between TTC and ACS was D-dimer. 
The number of patients with elevated (> 0.5 μg/mL) D-dimer was similar between TTC (14) and No-
CAD (15), but lower than in ACS (20). Both TTC and ACS had similar elevated hsCRP, fibrinogen, 
and vWF:Ag values, which were higher than was No-CAD (Table 5). 
Coronary risk factors in TTC differed from STEMI in lower BMI (26.1 kg/m2 (22.8 - 29.0) 
vs. 26.9 kg/m2 (24.2 - 31.6), p=0.025) and less dyslipidemia (57% vs. 83%, p=0.007); and from No-
CAD in lower BMI (26.1 kg/m2 (22.8 - 29.0) vs. 26.8 kg/m2 (24.5 - 30.5), p=0.038). The time from 
symptom onset to CAG was similar between TTC and ACS patients (48 hours (24 – 96) vs. 48 hours 
(24 – 90); p=0.94). Non-significant obstructions (≤ 50%) in CAG were evident in 47% of the TTC 
and 15% of the No-CAD. CAG of ACS patients showed single-vessel disease in 28%, two-vessel 
disease in 21% and three-vessel disease in 51%. From highest to lowest, pro-BNP values were in 
TTC 2528 ng/L (1397 - 5767), in ACS 810 ng/L (268 - 2372), and in No-CAD 197 ng/L (111 - 533) 
and differed among the groups (p<0.0001). 
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Table 5. Coagulation and acute-phase markers from plasma 
  TTC ACS No-CAD I II III 
            
44sCRP (mg/L) 7.13 (1.99-23.00) 9.44 (1.48-30.52) 1.44 (1.02-3.00) 0.200 <0.0001 <0.0001 
D-Dimer (μg/L) 0.31 (0.22-0.59) 0.39 (0.24-1.20) 0.38 (0.22-0.56) 0.019 0.370 0.064 
vWF:AG (%) 174.0 (139.0-215.0) 151.0 (132.0-210.0) 130.0 (98.0-169.0) 0.210 <0.0001 0.005 
Fibr (g/L) 3.90 (3.19-4.70) 4.40 (3.47-5.29) 3.52 (3.12-3.79) 0.092 0.005 <0.0001 
TAT (μg/mL) 3.80 (3.00-5.50) 4.10 (3.30-6.80) 3.60 (2.90-7.80) 0.500 0.290 0.560 
sGPV (ng/mL) 38.8 (33.50-55.20) 40.10 (33.00-56.20) 36.70 (27.30-53.30) 0.540 0.190 0.100 
              
 
F= fibrinogen, hsCRP = high-sensitivity C-reactive protein, sGPV = soluble glycoprotein V, TAT = thrombin 
antithrombin complex, vWF = von Willebrand factor 
I, TTC vs. ACS, p-value; II, TTC vs. No-CAD, p-value; III, ACS vs. No-CAD, p-value 
Median (interquartile range)           
 
For anticoagulant and antithrombotic medication see Table 6. All statistically differing 
parameters (low-molecular weight heparin, clopidogrel, aspirin, glycoprotein inhibitor, BMI, and 
dyslipidemia) were examined in multivariate analysis, but none predicted the laboratory parameters. 
 
Table 6. Number of patients on anticoagulation and antithrombotic medications 
    TTC ACS No-CAD I II III 
                
                
Clot lysis (<24h) 1 (2) 3 (6) 0 (0) 0.620 1.000 0.240 
Warfarin   5 (11) 0 (0) 4 (9) 0.060 1.000 0.120 
Aspirin   42 (89) 46 (98) 34 (72) 0.090 0.060 0.001 
Clopidogrel   32 (68) 38 (81) 6 (13) 0.150 <0.0001 <0.0001 
LMWH   45 (96) 42 (89) 1 (2) 0.240 <0.0001 <0.0001 
Glycoprotein IIb/IIIa inhibitor 18 (38) 19 (40) 0 (0) 0.830 <0.0001 <0.0001 
                
 
LMWH = low-molecular weight heparin 
I = TTC vs. ACS, p-value; II = TTC vs. No-CAD, p-value; III = ACS vs. No-CAD, p-value 
Median (interquartile range).             
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5.5.2. Matrix metalloproteinases (III) 
MMP-8 levels in ACS and TTC were similar, but were lower in controls. TIMP-1 levels showed 
a stepped rise from low in controls to TTC and highest in ACS (Figure 6). MMP-8 and TIMP-1 levels, 
and the MMP-8/TIMP-1 molar ratio were used to divide patients into tertiles. TIMP-1, but not MMP-
8 and MMP-8/TIMP-1 molar ratio, associated with ACS over TTC (3rd tertile vs 1st OR 4.52 (1.86 
- 11.00), p < 0.002). TIMP-1 remained independently associated with ACS in multivariate analysis.  
 
Figure 6. MMP-8 and TIMP-1 levels (ng/mL) and their ratio between ACS, TTC and controls. MMP-8 
= matrix metalloproteinase 8, TIMP-1 = tissue inhibitor of matrix metalloproteinase 1. Adapted from 
Parkkonen et. al. 2016 (III). 
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On-admission TnT levels were similar (0.3 μg/L (0.1-0.9) vs. 0.2 μg/L (0.1-0.6); p = 0.7) and 
unable to differentiate ACS and TTC (area under the curve (AUC) 0.522 (0.442-0.602; p > 0.05). 
TIMP-1 differentiated ACS from TTC with an area under the curve (AUC) of 0.679 (p < 0.0001) 
(Figure 7). TIMP-1 also improved the sensitivity and specificity of other significant differences (age, 
sex, smoking) in the c-statistics (AUC 0.821, 0.764 - 0.879 (p<0.0001) vs. 0.844, 0.783 - 0.906 
(p<0.0001), (p<0.01) (Figure 7). 
 
Figure 7. Left: In recognition of ACS, ROC curves show better sensitivity and specificity of on-
admission TIMP-1 (dark grey) over TnT (light grey). Right: In c-statistics, combination of TIMP-1 
and other risk factors (age, sex and smoking) improved the differentiation of ACS and TTC 
compared to other risk factors alone (light grey). Adapted from Parkkonen et. al. 2016 (III).  
 
EF from the LVG in TTC patients was abnormal (<50%) in 17 patients. The median EF was 53% 
(35 – 62). MMP-8 and TIMP-1 individually showed no association with LV function; however, 
MMP-8/TIMP-1 molar ratio correlated with EF (r=0.358; p=0.02). Of end-diastolic, end-systolic, or 
stroke volume, the EF was the only LVG measurement that correlated with the MMP-8/TIMP-1 
molar ratio. MMP-8, TIMP-1 levels and ratio between apical and mid-ventricular TTC were similar. 
The echocardiography EF in ACS had no association with MMP-8, TIMP-1 or MMP-8/TIMP-1 
molar ratio. 
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TTC with low < 50% EF had high TIMP-1 levels similar to those of ACS, but significantly lower 
MMP-8 levels. In fact, the MMP-8/TIMP-1 ratio was significantly lower in low-EF TTC and higher 
in normal-EF TTC than was in ACS. In normal-EF TTC, the TIMP-1 was lower than and MMP-8 
similar to ACS. 
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6. DISCUSSION 
During the time we conducted our studies, the number of TTC studies has increased substantially. 
The elegant animal model by Paur et al. (2009) has been one of the most interesting reports, shedding 
new light onto the pathogenesis of TTC [50]. Further studies hopefully can confirm whether the same 
mechanism applies to humans as well. The availability of larger cohorts and multicenter studies has 
revealed new insights. Recent large cohort reports have recognized a subset of patients at high risk 
during hospitalization, in opposition to the common perception of a benign disease [118,163].  
 Our work supports many of the previous concepts and theories in TTC. The complete 
material showed qualities in demographics, co-morbidities and medications similar to those in earlier 
reports, thus allowing direct comparison with others’ findings [5,11,12,90].  
 
6.1. Electrocardiography (I) 
In the search for TTC ECG criteria, we found ST-elevation less than 2 mm in lead V2 in the absence 
of ST-elevation in lead V1 was a specific finding in TTC patients, however, its sensitivity was less 
impressive. Overall, ST-elevation changes in anterior-STEMI patients were more distinctive and 
frequent than in TTC. Even though less frequently, ST-elevations were apparent in similar pattern in 
apical TTC as anterior STEMI with the exclusion of lead V1. Mid-ventricular TTC clearly differed 
—the patients had very modest ST-elevations and they appeared in only few leads. 
 Temporal evolution of ECG changes in TTC follow similar pattern to that of STEMI. 
T-wave inversion normally follows ST-elevation, and changes normalize within 1 to 2 weeks [56]. 
Primary negative T-waves could, therefore, be considered a sign of a longer delay to seek medical 
attention. Dib. et al. (2009) found no relation between delay from symptom onset and primary ECG 
finding, which suggests variability in primary ECG findings in TTC regardless of delay [104]. In 
many cases, however, the moment of pain onset is a very subjective perception. Therefore, the role 
of the delay remains a debatable in TTC ECG interpretations [164,165].  
 The point of measurement for ST-elevation affects the amplitude as well as the 
frequency. Current guideline of the European Society of Cardiology recommends using the J-point 
[31]. Many reports used the J-point + 80 milliseconds for measurement point, which may result in 
higher amplitude and frequency in cases with an upward ST-segment [98,99,104,105], thus making 
direct comparison of our results difficult. The best comparison is offered by the results of Tamura et 
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al. (2011) and Johnson et al. (2013), which utilize the same measurement point as does the current 
study [108,166]. Usage of similar measurement points in the future, and analysis of ST-segment 
morphology, could lead to more accurate results. 
 ST-depression is a rare finding in TTC, and some of the milder changes could possibly 
be explained by normal variation of the baseline. ST-depression appeared in only 6 TTC patients—3 
of those in lead aVR suggesting that in TTC reciprocal changes are rare, if not non-existent. The most 
promising earlier ECG criteria identified TTC with good sensitivity and specificity by combining ST-
depression in aVR and lack of ST-elevation in V1 [98]. Our results strongly disagree, due to the low 
incidence of ST-depression. Strangely, no T-wave changes were reported in the same study, raising 
the question whether their ST-depression changes were merely a combination of ‘late’ measurement 
point and negative T-wave. 
 Compared to anterior STEMI, apical TTC patients had frequent and high amplitude 
negative T-waves, especially in the chest leads. Mid-ventricular TTC had relatively scarce negative 
T-wave changes, which were in line with ST-segment findings. The only lead that differentiated both 
TTCs from the STEMI was aVL. This finding was rather specific, but its sensitivity was inadequate 
for clinical decision-making.  
 Although mid-ventricular TTC involves a large area of affected myocardium in LVG, 
the ECG changes remain few. The standard 12 leads cover mid-ventricular myocardium poorly. The 
affected myocardium projects horizontally to lead V2 and in the frontal plane to leads I and aVL, 
which explains the scarce ECG changes. Fittingly, of the 12 ECG leads ST-elevation showed in only 
2 (I and V2) and negative T-waves in 3 (I, aVL and V2) in line with others’ findings [105]. ST-
elevation was present in half and negative T-waves in all our mid-ventricular TTC patients. None of 
the mid-ventricular patients fulfilled the criteria for ST-elevation myocardial infarction [31]. Mid-
ventricular TTC patients could potentially pose a diagnostic problem. Mild symptoms leading to 
longer delay from symptom onset to medical contact and few or non-existent ECG findings could 
result in misdiagnosis of non-cardiac chest pain. Luckily, in the absence of severe heart failure, TTC 
has a good prognosis. 
 A surprisingly low number of our TTC patients fulfilled the ECG criteria for STEMI. 
Another study focused on those TTC patients fulfilling the STEMI criteria, comparing female TTC 
patients were compared to female STEMI patients with poor results. In that study, trial of previous 
criteria by Kurisu et al and Johnson et al. (2009) produced less impressive results than in their original 
publications [105,108]. Vervaat et. al. (2015) had the best result with a frontal plane ST-vector 60 
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degrees distinguishing TTC from STEMI with 49% sensitivity and 93% specificity [167]. Although 
a smaller number of TTC patients than initially thought caused a differential diagnostic problem with 
STEMI, no ECG interpretation should delay the angiography and treatment in cases with ST-
elevation. 
 In MI, Q-waves are related to a large area of stunned myocardium and small infarct 
size, which is usually seen after a rapid revascularization [51,101]. Such a finding could support the 
aborted-MI theory behind TTC. Sharkey et al (2008), however, found that despite, a similar incidence 
of Q-waves in TTC and ACS, TTC patients showed no signs of necrosis in magnetic resonance 
imaging [101]. In our study, the incidence of Q-waves did not differentiate ACS from TTC; and 
therefore could not rule out the hypothetical aborted MI. 
 
6.2. Coagulation (II) 
To rule out any atherothrombotic event behind the TTC, we compared TTC and ACS patients in the 
acute phase for coagulation factors. The more systemic approach allowed us to tackle the 
shortcomings of previous imaging studies assessing the role of aborted MI and microvascular 
thrombosis. TTC associated with a significant increase in coagulation factors known to be acute-
phase proteins, but showed no plausible signs of abnormal fibrin formation. These results argue 
against an acute thrombotic situation and are fitting for the catecholamine-excess theory.  
Elevated D-dimer level marks a hypercoagulable state, thrombus formation, and 
degradation. In our study, the TTC- and No-CAD patients both had less frequent elevated D-dimer 
levels than ACS patients had. D-dimer values were also higher in ACS than in TTC, despite similar 
medication and acute phase reaction. These results suggest less thrombosis, if any, in TTC than in 
ACS. 
 A preceding excessive-stress event or other increased sympathetic activity in the 
majority of TTC cases manifests as elevated catecholamine levels. The coagulation system and 
platelet function are directly influenced by the levels of epinephrine and norepinephrine. The 
catecholamines, especially epinephrine, lead to the release of F VIII and von Willebrand factor from 
the endothelial cells [137]. In a stressful situation, such physiological pro-thrombotic changes cause 
no thrombosis in healthy vessels, but may exaggerate thrombosis in the presence of endothelial 
erosion or atherosclerotic plaque rupture. In our study, TTC and ACS patients both had high levels 
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of von Willebrand factor. TTC patients, however, had no convincing signs of thrombus formation in 
other laboratory assays or in angiography—unlike ACS patients.  
 An acute phase reaction is a defensive reaction against toxic or infectious agents. Stress-
induced myocardial damage is also characterised by a similar cytokine-induced increase in acute 
phase proteins like C-reactive protein and in coagulation factors such as fibrinogen, von Willebrand 
factor, F VIII and prothrombin.  Elevated levels of such proteins were akin in TTC and ACS and were 
higher than in No-CAD. In conjunction with D-dimer findings, these results suggest that TTC exhibits 
a similar acute phase reaction than ACS but not thrombosis. 
 Platelet activation plays an important role in arterial thrombosis both the platelets 
forming the main part of the arterial thrombus. Two studies have compared platelet activation 
between ACS and TTC in the acute phase with controversial results. The first study showed elevated 
platelet activation marker CD26P expression and higher plasma interleukin-6 levels reflecting 
enhanced platelet activation in ACS compared to activation in TTC in the acute phase [168]. The 
other study revealed platelet activation evaluated by integrin glycoprotein IIb/IIIa and P-selectin 
expression in the acute phase as similar for TTC and for ACS patients [169]. Interestingly, platelet 
activation at follow-up was related to elevated acute-phase epinephrine levels [169].  
In our TTC population, sGPV, a marker for platelet activation, was not increased; nor 
did we observe any significant difference in sGPV values between the ACS and TTC groups. ACS 
patients had borderline higher levels of sGPV than did non-CAD patients, as expected. Our results 
did not suggest platelet activation in TTC, but the difference between ACS and controls was only 
moderate, thus challenging the sGPV’s ability to identify platelet activation in ACS. 
No LV thrombus was detectable in any of the TTC patients. However, none of our 
patients underwent cardiac magnetic resonance imaging, which would have allowed more 
comprehensive evaluation by LVG [138]. 
We found in TTC patients no biochemical or angiographic evidence of thrombus 
formation or degradation, which in conjunction with others reports of negative imaging findings of 
TTC patients’ coronaries, suggests a non-thrombotic cause for TTC. An extensive metabolic defect 
exceeding the perfusion defect in the TTC-affected myocardium, favors a metabolic origin for the 
microvascular dysfunction and opposes any thrombotic origin [60]. Furthermore, a larger study later 
reported similar coagulation results [170]. Although the role of microvascular dysfunction and 
perfusion defect remains unclear in the pathogenesis of TTC, our results here support a non-
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thrombotic cause and argue against the existence of microvascular thrombosis or atherosclerotic 
plaque erosion.  
 
6.3. Matrix metalloproteinases (III) 
MMP-8 and TIMP-1 have been implicated in ACS. Due to the probable difference between TTC and 
ACS pathophysiology, we hypothesized that MMP-8 and TIMP-1 can differentiate TTC from ACS. 
Only one small series of TTC patients’ MMP and TIMP profiles exists and it contains no direct 
comparison to ACS [156]. Furthermore, the effects of MMPs and TIMPs in HF and other 
cardiomyopathies led us to explore whether MMP-8 and TIMP-1 levels affect the severity of the LV 
impairment in TTC. 
TIMP-1 was significantly higher in ACS than in TTC, but curiously TTC also had 
higher levels than did controls. On admission, TIMP-1 could differentiate TTC from ACS with better 
sensitivity and specificity than did TnT. TnT is cardiac specific, but not specific to ACS. Within a 
few hours after ischemic myocardial damage, TnT levels rise. Therefore, on admission, TnT levels 
might not be able to differentiate ACS from other heart diseases. In the current study, the highest TnT 
value differed between ACS and TTC, but the on-admission levels were similar and in both cases 
low. The differing TIMP-1 levels provided improvement in early non-invasive diagnostics of ACS 
vs TTC. TIMP-1 also improved the accuracy of differentiation more than other significant differences 
(age, sex, and smoking) between the groups did. 
Heart failure (HF) is marked by changes in the ECM, which serves as barrier against 
pathologic stress, but ultimately contributes to pathogenesis. The changes depend upon the etiology 
of the condition [145,171]. In pressure-overload HF (for instance from hypertension), the decreased 
proteolysis leads to increased ECM volume, especially accumulation of type-I collagen. In such cases, 
the myocardium exhibits a pro-fibrotic low-MMP and high-TIMP balance [145,146]. The increased 
fibrosis causes myocardial stiffness. Similar fibrosis in hypertrophic cardiomyopathy linearly 
associates with decreased regional contractility [172]. 
In TTC patients, endomyocardial biopsies show inflammation and transient interstitial 
fibrosis in the acute phase, which resolves after functional recovery [47,155]. The increased fibrosis 
mainly comprises type-I collagen and subsequently shows an increased type-I/III collagen ratio. In 
the ECM, the type-III collagen provides the elastic properties and type-I the load bearing properties, 
and such an altered ratio associates with increased stiffness [155]. None of the endomyocardial biopsy 
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studies found signs of post-ischemic necrosis; however, contraction band necrosis, also associated 
with pheochromocytoma, did occur [47,155,173]. MRI of TTC patients supports such findings and 
reveals signs edema and inflammation, but no convincing signs of necrosis fitting to ischemic damage 
[90]. 
In our results, in TTC patients, the MMP-8/TIMP-1 molar ratio was associated to EF. 
Low-EF TTC had lower MMP-8 levels and higher TIMP-1 levels than did normal-EF TTC. Such a 
pro-fibrotic ratio may reflect the increased interstitial fibrosis seen in previous endomyocardial 
biopsies. Moreover, such an increased fibrosis may explain the worse LV function in some proportion 
of TTC patients. The correlation of MMP-8/TIMP-1 ratio with EF supports this theory.   
 MMP-8 differentiated ACS and TTC patients from controls, but not from each other. 
Clearly, MMP-8 plays a role in both ACS and TTC, but their origin appear to differ. Evidence 
suggests that acute-phase MMP-8 and TIMP-1 ACS a originate from atherosclerotic plaques 
[144,154]. In TTC, however, the relationship of acute MMP-8/TIMP-1 molar ratio to LV EF, in 
conjunction with the previous endomyocardial-biopsy findings, suggest myocardium as their origin. 
Direct proof of what ultimately leads to the altered MMP-8 and TIMP-1 levels is lacking. HsCRP 
correlated with MMP-8 and TIMP-1. Accordingly, the alteration in TTC patients’ MMP-8 and TIMP-
1 levels may in fact be linked to inflammatory response. On the other hand, elevated catecholamines, 
especially norepinephrine, are known to affect MMP and TIMP levels. The elevated catecholamine 
levels in TTC may be cause of the altered MMP-8 and TIMP-1 levels [174-176]. 
 
6.4. Limitations and future studies 
The greatest limiting factor in our study was sample size. Even with the rising TTC incidence in the 
7 years of our study, a collection of a large population in a single center would require years of patient 
enrollment. Such restrictions call for large multicenter studies in the future to achieve more accurate 
view of this syndrome. 
 Even though the catecholamine hypothesis seems the most plausible explanation for 
TTC pathogenesis of TTC, some of the results display variability similar to that in coronary spasm 
and microvascular dysfunction. The catecholamine theory is based heavily on one study with a 
relatively small number of high-catecholamine-level patients [177], later studies, however, show such 
results in only a small proportion of TTC patients [45,46]. Our results (I, II) were in line with the 
catecholamine theory, but the uncertain high acute levels in TTC need confirmation in a larger 
population. 
 55 
 Two of our studies (I, II), had common problems associated with their retrospective 
study setting. The dynamic changes in ECG and biochemical measures were difficult to evaluate, due 
to partial information concerning time delays in seeking medical care and blood sampling. Moreover, 
no serial sampling to assess the temporal effect was possible. Some of the data were not available for 
all the patients, which limited sample size in some cases. A well-designed prospective study with 
standardized serial samples would solve some of these limitations. 
 The methods of Studies II and III allowed us to observe the possible pathophysiologic 
mechanisms by means of circulating biomarkers. The approach and the study setting, however, 
prevented us from verifying our findings at the cellular level, or by intracoronary imaging or by 
endomyocardial biopsies. Such methods would have provided more solid evidence for these results 
and further studies with such methods are, therefore, warranted. 
 The recently proposed multifactorial theory of TTC pathophysiology seems appealing 
in the light of these results [20,178]. Many of the suggested mechanisms for TTC, such as aborted 
MI, microvascular dysfunction, and coronary spasm are recognized as individual entities and known 
as MI without obstructive coronary atherosclerosis [179]. Although all our patients fulfilled the TTC 
criteria, cardiac magnetic resonance imaging, IVUS/OCT, and endomyocardial biopsies would have 
benefitted their assessment. Moreover, such methods would have allowed better evaluation of each 
patient’s individual characteristics and could have provided new associations supporting the 
multifactorial theory. In a clinical setting, these entities tend to overlap, due to their very similar 
symptoms and findings and may also be underestimated after MI rule-out. 
As the hunt for the mechanisms regarding TTC pathophysiology continues, the results 
of this work support the most probable theory, which is the catecholamine theory. Moreover, these 
findings suggesting fibrosis in the MMP study reveal a possible multifactorial pathogenesis. The 
recent increase in TTC populations should offer exciting new insights and may help to unravel the 
mystery. 
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7. CONCLUSIONS 
? ECG analysis offered no reliable criteria to differentiate acute TTC patients from ACS patients. 
A surprisingly small percentage of TTC patients posed a true differential diagnostic problem 
versus STEMI patients. The mid-ventricular TTC patients showed very subtle if not obsolete 
ECG changes perhaps leading to misdiagnosis. 
? TTC and ACS patients displayed similar acute phase reactions according to their laboratory 
values. Despite their pro-thrombotic state, the d-dimer results differed from those of the ACS 
patients and were similar to those of healthy controls arguing against thrombosis as the origin of 
TTC. Our findings supported catecholamine excess theory but oppose a concept of aborted MI as 
the basis of the TTC pathogenesis. 
? A low MMP-8/TIMP-1 ratio may reflect increased ECM fibrotic content and more severely 
impaired LV function. A high TIMP-1 may be beneficial in differentiation of acute TTC from 
ACS. 
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